AstraZeneca Trial Shows Improved Outcomes in Liver Cancer Study
WILMINGTON, DE — AstraZeneca reported that its drug combination including IMFINZI and IMJUDO, used with lenvatinib and transarterial chemoembolization, improved progression-free survival in patients with unresectable liver cancer eligible for …
AstraZeneca Trial Shows Improved Outcomes in Liver Cancer Study Read More